Endurance (Cayman) Ltd Svf Sells 132,978 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) Stock

Vir Biotechnology, Inc. (NASDAQ:VIRGet Rating) major shareholder Endurance (Cayman) Ltd Svf sold 132,978 shares of the stock in a transaction on Monday, November 7th. The stock was sold at an average price of $27.22, for a total value of $3,619,661.16. Following the sale, the insider now directly owns 21,953,302 shares of the company’s stock, valued at $597,568,880.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Endurance (Cayman) Ltd Svf also recently made the following trade(s):

  • On Monday, August 15th, Endurance (Cayman) Ltd Svf sold 122,564 shares of Vir Biotechnology stock. The stock was sold at an average price of $27.99, for a total value of $3,430,566.36.

Vir Biotechnology Stock Up 5.7 %

VIR opened at $27.43 on Friday. The firm has a market cap of $3.65 billion, a P/E ratio of 3.23 and a beta of -0.01. Vir Biotechnology, Inc. has a 52 week low of $18.05 and a 52 week high of $58.00. The business’s fifty day simple moving average is $21.55 and its 200 day simple moving average is $24.16.

Vir Biotechnology (NASDAQ:VIRGet Rating) last posted its quarterly earnings data on Tuesday, August 9th. The company reported ($0.58) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.41). The company had revenue of $40.60 million for the quarter, compared to analyst estimates of $211.14 million. Vir Biotechnology had a net margin of 52.29% and a return on equity of 60.66%. The firm’s revenue was down 77.1% on a year-over-year basis. During the same period in the previous year, the business earned $0.46 EPS. As a group, equities analysts expect that Vir Biotechnology, Inc. will post 3.65 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. TheStreet raised Vir Biotechnology from a “d” rating to a “c-” rating in a report on Monday, October 10th. Morgan Stanley increased their price objective on Vir Biotechnology from $15.00 to $18.00 and gave the stock an “underweight” rating in a research report on Friday, November 4th. SVB Leerink increased their price objective on Vir Biotechnology from $40.00 to $45.00 and gave the stock an “outperform” rating in a research report on Friday, November 4th. HC Wainwright reiterated a “buy” rating and issued a $125.00 price objective on shares of Vir Biotechnology in a research report on Thursday, July 14th. Finally, Barclays dropped their price target on Vir Biotechnology to $67.00 in a research report on Monday, August 15th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $52.50.

Institutional Trading of Vir Biotechnology

A number of hedge funds have recently added to or reduced their stakes in VIR. State Street Corp boosted its stake in Vir Biotechnology by 65.9% in the 1st quarter. State Street Corp now owns 4,193,764 shares of the company’s stock worth $107,864,000 after buying an additional 1,665,657 shares during the last quarter. Renaissance Technologies LLC lifted its stake in shares of Vir Biotechnology by 495.8% in the 2nd quarter. Renaissance Technologies LLC now owns 562,400 shares of the company’s stock valued at $14,324,000 after purchasing an additional 468,000 shares in the last quarter. Principal Financial Group Inc. lifted its stake in shares of Vir Biotechnology by 1,713.0% in the 2nd quarter. Principal Financial Group Inc. now owns 471,935 shares of the company’s stock valued at $12,021,000 after purchasing an additional 445,904 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Vir Biotechnology by 5.8% in the 1st quarter. Vanguard Group Inc. now owns 7,758,397 shares of the company’s stock valued at $199,546,000 after purchasing an additional 428,266 shares in the last quarter. Finally, Qube Research & Technologies Ltd acquired a new position in shares of Vir Biotechnology in the 1st quarter valued at about $8,460,000. 64.55% of the stock is owned by institutional investors and hedge funds.

About Vir Biotechnology

(Get Rating)

Vir Biotechnology, Inc, a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus.

Further Reading

Insider Buying and Selling by Quarter for Vir Biotechnology (NASDAQ:VIR)

Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.